1. Cross-protection against variants within a subtype after intranasal immunization with vaccine from MDCK cell-adapted Vac-3 P22.
Cross-protection against variants within a subtype after intranasal immunization with vaccine from MDCK cell-adapted Vac-3 P22. Mice (5 per group) were inoculated intranasally twice with PBS (no Vaccine) or with 1, 3, or 10 μg of formalin-inactivated whole-virion vaccine from MDCK cell-adapted Vac-3 P22 (Vaccine). Fourteen days after the final immunization, the mice were infected with MDCK cell-adapted Vac-3 P22 (H5N1; 106 PFU) (A), A/Hong Kong/483/1997 (HK/483/97) (highly pathogenic, H5N1, clade 0; × EID50) (B), or A/peregrine falcon/Hong Kong/810/2009 (PF/HK/810/09) (highly pathogenic, H5N1, clade 2.3.4; × EID50) (C), and mortality status was assessed. ∗, P < 0.05 versus the group inoculated intranasally with PBS.
Ahmad M. Haredy et al. Clin. Vaccine Immunol. 2013; doi: /CVI